News

Woolsey Pharmaceuticals Emerges from Stealth Mode to Announce Patients Enrolled in Two New CNS Studies

PRESS RELEASE One trial seeks to reduce wandering in dementia patients; the other targets two rare, deadly neurodegenerative diseases. NEW YORK, February 18, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced dosing of the first patient with BRAVYL in its FOUND (Fasudil fOr Uncontrolled waNDering) study for Alzheimer’s and […]

Woolsey Pharmaceuticals Emerges from Stealth Mode to Announce Patients Enrolled in Two New CNS Studies Read More »

Woolsey Pharmaceuticals’ Financing Is Oversubscribed; Two Board Members Named

NEW YORK, NY – March 11, 2020 – Woolsey Pharmaceuticals announced today that it completed a round of financing that will fund operations through the completion of a planned clinical study. The amount was not disclosed but the financing was substantially oversubscribed, according to company officials. The Company also announced the appointment of two outside

Woolsey Pharmaceuticals’ Financing Is Oversubscribed; Two Board Members Named Read More »

Embark Healthcare Launches Two New Repurposed Drug Companies

NEW YORK, NY – December 2, 2019 –Embark Healthcare announced today the launch of two new repurposed drug companies, Woolsey Pharmaceuticals and Learmont Pharmaceuticals.  EMBARK HEALTHCARE is made up of a diverse group of companies within the pharmaceutical industry. While each is unique in the field of medicine it is pursuing, all are “Indication Discovery Companies,”

Embark Healthcare Launches Two New Repurposed Drug Companies Read More »

Embark Healthcare’s New Name Reflects Emphasis on Repurposing Therapeutics

NEW YORK, NY – December 2, 2019 – After almost two decades since its inception, Carrot Capital Healthcare Partners announces a corporate name change to Embark Healthcare.  The new name better reflects our role as an “Indications Discovery Company.” Embark Healthcare doesn’t discover new drugs. Instead, we discover new ways to use existing drugs for other

Embark Healthcare’s New Name Reflects Emphasis on Repurposing Therapeutics Read More »

Woolsey Pharmaceuticals Signs License Agreement With Asahi Kasei Pharma for Exclusive Rights to Fasudil

NEW YORK, NY – November 25, 2019 – Woolsey Pharmaceuticals announced today that it completed a license agreement with Japanese pharmaceutical company Asahi Kasei Pharma Corporation, for rights to its drug, fasudil. The agreement grants Woolsey Pharmaceuticals the rights to develop and manufacture, and exclusive rights to commercialize any formulations (other than ophthalmic and injectable forms)

Woolsey Pharmaceuticals Signs License Agreement With Asahi Kasei Pharma for Exclusive Rights to Fasudil Read More »

Biogen Begins Brain Contusion Study, Enrolls First Patient

NEW YORK, NY – October 22, 2019 – Embark Healthcare announced today that Biogen (Nasdaq:BIIB), an American multinational biotechnology company based in Cambridge, Massachusetts and specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide, reported that it enrolled the first patient in a phase 2 brain contusion

Biogen Begins Brain Contusion Study, Enrolls First Patient Read More »